UBS Maintains Neutral on RxSight, Raises Price Target to $6.3

Benzinga Newsdesk www.benzinga.com Positive 60.9%

Neg 0% Neu 0% Pos 60.9%

UBS analyst Patrick Wood maintains RxSight (NASDAQ:RXST) with a Neutral and raises the price target from $5.5 to $6.3.

Comments

No comments yet. Be the first!